Law Offices of Todd M. Garber Announces Investigation of Vanda Pharmaceuticals, Inc.
04 7월 2013 - 12:32PM
Business Wire
The Law Offices of Todd M. Garber announces that it is
investigating potential claims against Vanda Pharmaceuticals, Inc.
(“Vanda” or the “Company”) (NASDAQ:VNDA) concerning possible
violations of federal securities laws. The investigation focuses on
certain statements issued by Vanda between December 18, 2012 and
June 18, 2013 regarding the Company’s business and financial
prospects.
Vanda is a biopharmaceutical company engaged in the development
and commercialization of products for the treatment of central
nervous system disorders. The Company’s product tasimelteon -- a
treatment for circadian rhythm sleep disorders (CRSD) -- is
currently in clinical development for a serious, rare CRSD known as
“Non-24.” The investigation concerns allegations that the Company
issued false and misleading statements or failed to disclose
material adverse facts concerning the Phase III clinical trials for
tasimelteon, including (1) whether the primary endpoint installed
to assess tasimelteon’s efficacy and safety was replaced by the
Company with an endpoint that was not endorsed by the Food and Drug
Administration and had never been used before in sleep-drug
clinical trials, and (2) whether tasimelteon demonstrated any
discernible difference in efficacy and safety in nighttime total
sleep between those patients deemed to have Non-24 and those
patients with a normal circadian rhythm.
If you purchased Vanda stock during the foregoing period, if you
have information or would like to learn more about these claims, or
if you purchased Vanda shares prior to December 18, 2012 and wish
to discuss these matters, please contact Todd M. Garber, Esquire,
of the Law Offices of Todd M. Garber, by telephone at 213-700-7262
or by email to info@toddgarberlaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
The Law Offices of Todd M. GarberTodd M. Garber, Attorney at
Law213-700-7262info@toddgarberlaw.com
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024